
Bristol
NHS Blood and Transplant Gene Therapy Hub
Due to be fully operational at the start of 2023, the new Hub will support early phase academic-led gene therapy trials and facilitate the provision of cost-effective viral vectors and plasmid DNA to stimulate the UK’s gene therapy sector.
The Hub, led by Dr Jon Smythe and Dr Paul Lloyd-Evans, will provide viral vector manufacturing, training and support services for academic-led groups seeking Adeno Associated Viral (AAV), Lentiviral (LV) vectors and plasmid DNA at GMP and research-grade qualities. It will also support academic-led teams in the translation of their research to the clinic and work with the other Hubs to develop, optimise and deliver a comprehensive training package to generate a highly skilled workforce, serving both the academic and commercial gene therapy communities.
People
- Director: Dr Jon Smythe
- Co-Director: Dr Paul Lloyd-Evans
- Viral Vector Hub Manager: Dr Sujith Sebastian
- Project Manager: Charlotte McHugh
- Business Development Manager, Clinical Biotechnology Centre: Hollie Yaxley
- Head of Business Development, Cellular & Molecular Therapies: Teresina Pinnington